GREAT NEWS for hamsters!
A high dose of favipiravir, however, had a potent effect. A few days after the infection, the virologists detected hardly any infectious virus particles in the hamsters that received this dose and that had been infected intranasally. Moreover, hamsters that were in a cage with an infected hamster and had been given the drug did not develop an obvious infection. Those that had not received the drug all became infected after having shared a cage with an infected hamster.KU Leuven. “Hydroxychloroquine does not counter SARS-CoV-2 in hamsters, high dose of favipiravir does: study.” ScienceDaily. ScienceDaily, 9 October 2020. www.sciencedaily.com/releases/2020/10/201009162432.htm.
Hopefully good news for humans.
Favipiravir: A new and emerging antiviral option in COVID-19
Favipiravir was first used against SARS-CoV-2 in Wuhan at the very epicenter of the pandemic. Then, as the pandemic spread to Europe, this drug received approval for emergency use in Italy, and currently has been in use in Japan, Russia, Ukraine, Uzbekistan, Moldova, and Kazakhstan. Approval has also recently been granted in Saudi Arabia and the UAE. Thereafter, Turkey, Bangladesh, and most recently Egypt have also seen recent commercial launches. In June 2020, favipiravir received the DCGI approval in India for mild and moderate COVID-19 infections. As of the 23rd of July, 2020; there are 32 studies registered on clinicaltrials.gov to assess the utility of this drug in the management of COVID-19 (3 completed, 12 recruiting).1Favipiravir: A new and emerging antiviral option in COVID-19 — http://Med J Armed Forces India. 2020 Sep 2 doi: 10.1016/j.mjafi.2020.08.004 [Epub ahead of print]